Breztri Shortage Update: What Patients Need to Know in 2026

If you've had trouble filling your Breztri Aerosphere prescription recently, you're probably wondering: is there actually a shortage? The answer is nuanced — and knowing the full picture will help you take the right steps to keep your COPD treatment on track. In this 2026 update, we cover Breztri's current supply status, what's driving availability challenges, and what you can do right now.

Is Breztri Aerosphere in an Official Shortage in 2026?

As of 2026, Breztri Aerosphere is NOT listed on the FDA's official drug shortage database. This means no formal, nationwide manufacturing shortage has been declared by AstraZeneca. That's the good news.

The challenging news: many patients across the United States are still reporting difficulty filling their Breztri prescriptions at local pharmacies. This gap between "no official shortage" and the real-world experience of patients is real, and it's driven by several supply-and-demand factors that disproportionately affect brand-name specialty inhalers.

What's Driving Breztri Availability Problems in 2026?

1. Surging Demand After Asthma Approval

In April 2026, the FDA approved Breztri Aerosphere as the first single-inhaler triple therapy for asthma in patients aged 12 and older — a major second indication that significantly expands the potential patient population. With more prescribers now writing Breztri for asthma in addition to COPD, demand has grown substantially. Distribution networks and pharmacy ordering patterns haven't fully caught up, creating sporadic stock gaps.

2. Brand-Name Only With No Generic Competition

All of the world's Breztri supply comes from one source: AstraZeneca. There is no generic version of Breztri, and none is expected until approximately 2038. When a single manufacturer controls the entire supply of a drug and demand increases rapidly, any production or distribution delays immediately result in real-world shortages at pharmacies. There is no alternative supplier to fill the gap.

3. Insurance Barriers Creating a "Functional" Shortage

Even when Breztri is physically on pharmacy shelves, prior authorization requirements and step therapy hurdles mean many patients can't access it without jumping through insurance hoops first. Most insurers require patients to have tried and failed dual-therapy COPD inhalers before approving Breztri coverage. This creates a functional shortage: the medication exists, but the system prevents patients from obtaining it without administrative delays that can take weeks.

4. High Cash Price

Without insurance, a single Breztri inhaler costs approximately $670–$930 retail for a 30-day supply. This price barrier means patients without adequate commercial insurance coverage often cannot afford Breztri even when it's readily available. For lower-income patients without commercial insurance, this is effectively a shortage — the drug exists but is inaccessible.

What Should You Do If You Can't Find Breztri?

Here are the most effective steps COPD and asthma patients can take right now:

Find in-stock pharmacies: Use medfinder to check which pharmacies near you currently have Breztri in stock. medfinder calls pharmacies on your behalf and texts you the results.

Request early refills: Start refill requests 7–14 days before you run out. This gives your pharmacy time to order Breztri if they don't currently stock it.

Try independent pharmacies: Independent pharmacies sometimes have different supply chains and may have Breztri when retail chains are out.

Apply for AstraZeneca savings programs: If cost is the barrier, the Breztri Zero Pay program may reduce costs to $0 for eligible commercially insured patients. The AZ&Me program helps uninsured patients who meet income requirements.

Talk to your doctor about alternatives: Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is the only other FDA-approved triple-combination COPD inhaler and may be covered differently on your insurance.

Looking Ahead: Will Breztri Availability Improve?

AstraZeneca produces Breztri in facilities that serve more than 90 countries worldwide. The company has significant manufacturing investment in this product, and the new asthma indication represents major commercial opportunity. This gives AstraZeneca strong incentives to scale production to meet growing demand. As pharmacies adjust their ordering patterns to reflect the larger patient population, localized shortages should decrease over time.

In the meantime, your best strategy is proactive refill management and using all available tools to locate in-stock pharmacies. Read our guide on how to find Breztri in stock near you for practical, step-by-step advice.